CIBC Asset Management Inc bought a new stake in shares of Takeda Pharmaceutical Co Ltd (NYSE:TAK) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 721,739 shares of the company’s stock, valued at approximately $14,702,000.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in TAK. Hudock Capital Group LLC bought a new stake in Takeda Pharmaceutical during the first quarter worth approximately $26,000. Contravisory Investment Management Inc. bought a new stake in Takeda Pharmaceutical during the first quarter worth approximately $28,000. Shine Investment Advisory Services Inc. bought a new stake in Takeda Pharmaceutical during the first quarter worth approximately $28,000. Parallel Advisors LLC bought a new stake in Takeda Pharmaceutical during the first quarter worth approximately $33,000. Finally, First Hawaiian Bank bought a new stake in Takeda Pharmaceutical during the first quarter worth approximately $35,000. Institutional investors own 3.63% of the company’s stock.
Shares of NYSE TAK opened at $19.49 on Tuesday. The company has a current ratio of 3.06, a quick ratio of 2.81 and a debt-to-equity ratio of 1.19. Takeda Pharmaceutical Co Ltd has a 1-year low of $15.50 and a 1-year high of $21.99. The company has a market cap of $30.45 billion, a price-to-earnings ratio of 18.21, a P/E/G ratio of 65.67 and a beta of 0.66.
WARNING: “CIBC Asset Management Inc Buys New Stake in Takeda Pharmaceutical Co Ltd (TAK)” was published by Rockland Register and is the sole property of of Rockland Register. If you are reading this article on another publication, it was stolen and reposted in violation of United States & international copyright laws. The correct version of this article can be viewed at https://rocklandregister.com/2019/05/14/cibc-asset-management-inc-buys-new-stake-in-takeda-pharmaceutical-co-ltd-tak.html.
About Takeda Pharmaceutical
Takeda Pharmaceutical Company Limited, together with its subsidiaries, engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. The company provides medicines in various therapeutic areas comprising gastroenterology, oncology, and neuroscience; and vaccines.
Recommended Story: What economic reports are most valuable to investors?
Want to see what other hedge funds are holding TAK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Takeda Pharmaceutical Co Ltd (NYSE:TAK).
Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.